| Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial N Katsumata, M Yasuda, F Takahashi, S Isonishi, T Jobo, D Aoki, H Tsuda, ... The Lancet 374 (9698), 1331-1338, 2009 | 892 | 2009 |
| Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or … N Katsumata, M Yasuda, S Isonishi, F Takahashi, H Michimae, E Kimura, ... The Lancet Oncology 14 (10), 1020-1026, 2013 | 540 | 2013 |
| Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505 R Kitagawa, N Katsumata, T Shibata, T Kamura, T Kasamatsu, ... Journal of clinical oncology 33 (19), 2129-2135, 2015 | 422 | 2015 |
| Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer M Ono, H Tsuda, C Shimizu, S Yamamoto, T Shibata, H Yamamoto, ... Breast cancer research and treatment 132, 793-805, 2012 | 374 | 2012 |
| Effect of communication skills training program for oncologists based on patient preferences for communication when receiving bad news: a randomized controlled trial M Fujimori, Y Shirai, M Asai, K Kubota, N Katsumata, Y Uchitomi Journal of clinical oncology 32 (20), 2166-2172, 2014 | 278 | 2014 |
| Psychological distress following first recurrence of disease in patients with breast cancer: prevalence and risk factors H Okamura, T Watanabe, M Narabayashi, N Katsumata, M Ando, I Adachi, ... Breast cancer research and treatment 61, 131-137, 2000 | 217 | 2000 |
| Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02 K Shimozuma, Y Ohashi, A Takeuchi, T Aranishi, S Morita, K Kuroi, ... Supportive care in cancer 17, 1483-1491, 2009 | 212 | 2009 |
| Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method T Isojima, A Shimatsu, S Yokoya, K Chihara, T Tanaka, N Hizuka, ... Endocrine journal 59 (9), 771-780, 2012 | 201 | 2012 |
| Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients S Park, C Shimizu, T Shimoyama, M Takeda, M Ando, T Kohno, ... Breast cancer research and treatment 99, 9-17, 2006 | 190 | 2006 |
| Relationship between outpatients’ perceptions of physicians’ communication styles and patients’ anxiety levels in a Japanese oncology setting T Takayama, Y Yamazaki, N Katsumata Social science & medicine 53 (10), 1335-1350, 2001 | 182 | 2001 |
| Construction and validation of a practical prognostic index for patients with metastatic breast cancer. N Yamamoto, T Watanabe, N Katsumata, Y Omuro, M Ando, H Fukuda, ... Journal of clinical oncology 16 (7), 2401-2408, 1998 | 161 | 1998 |
| Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer Y Tanabe, K Hashimoto, C Shimizu, A Hirakawa, K Harano, M Yunokawa, ... International journal of clinical oncology 18, 132-138, 2013 | 157 | 2013 |
| Physician–patient communication and patient satisfaction in Japanese cancer consultations H Ishikawa, T Takayama, Y Yamazaki, Y Seki, N Katsumata Social science & medicine 55 (2), 301-311, 2002 | 146 | 2002 |
| Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery N Taira, K Shimozuma, T Shiroiwa, S Ohsumi, K Kuroi, S Saji, M Saito, ... Breast cancer research and treatment 128, 735-747, 2011 | 129 | 2011 |
| Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized … K Shimozuma, Y Ohashi, A Takeuchi, T Aranishi, S Morita, K Kuroi, ... Supportive Care in Cancer 20, 3355-3364, 2012 | 117 | 2012 |
| Serum levels of cytokines in patients with untreated primary lung cancer. N Katsumata, K Eguchi, M Fukuda, N Yamamoto, Y Ohe, F Oshita, ... Clinical cancer research: an official journal of the American Association …, 1996 | 113 | 1996 |
| Histology according to the Revised European-American Lymphoma Classification significantly predicts the prognosis of ocular adnexal lymphoma M Nakata, Y Matsuno, N Katsumata, T Takenaka, Y Kobayashi, ... Leukemia & lymphoma 32 (5-6), 533-543, 1999 | 103 | 1999 |
| Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study RA Burger, MF Brady, MA Bookman, BJ Monk, JL Walker, HD Homesley, ... Journal of clinical oncology 32 (12), 1210-1217, 2014 | 96 | 2014 |
| Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan T Kouno, N Katsumata, H Mukai, M Ando, T Watanabe Japanese Journal of Clinical Oncology 33 (6), 309-313, 2003 | 91 | 2003 |
| Multicenter, phase II, placebo‐controlled, double‐blind, randomized study of aprepitant in Japanese patients receiving high‐dose cisplatin T Takahashi, E Hoshi, M Takagi, N Katsumata, M Kawahara, K Eguchi Cancer science 101 (11), 2455-2461, 2010 | 86 | 2010 |
